Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
University of Southern California
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05791448CT.gov AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Cholangiocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| au409 (this asset) | University of Southern California | P1 | CC · 43 |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P3 | BB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | B |
| Etomidate | Cheju Halla General Hospital | P4 | B |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | B |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P3 | B |
| Midazolam | Cheju Halla General Hospital | P4 | B |
| Meperidine | Cheju Halla General Hospital | P4 | B |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | B |
+42 more in the Cholangiocarcinoma cohort
Other indications for au409
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P1 | CC · 41 |
| Refractory Malignant Neoplasm | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. au409 in Cholangiocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/au409-cholangiocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →